Estrella Immunopharma, Inc. (ESLA): Nasdaq/NYSE listing notice — Estrella Immunopharma receives Nasdaq non-compliance notice for MVLS below $35M

Estrella Immunopharma, Inc.

Received Nasdaq notice on Aug 1, 2025 for failing to maintain minimum MVLS of $35M for 30 consecutive business days.
Non-compliance period identified as June 13, 2025 to July 31, 2025.
Company has 180 days, until Jan 28, 2026, to regain compliance with MVLS of $35M+ for 10 consecutive business days.
Also noted non-compliance with alternative listing rules 5550(b)(1) and 5550(b)(3).
No immediate effect on listing; Company will monitor and consider options but cannot assure regaining compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Estrella Immunopharma, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2), 5810(c)(3)(C)

Exact text from the filing

August 1, 2025, Estrella Immunopharma, Inc. (the “ Company ”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(2), which requires listed securities to maintain a minimum Market Value of Listed Securities (“ MVLS ”) of $35,000,000. The Company has not met this requirement for the 30 consecutive business days preceding the date of the notice. The notice indicated the period of non-compliance was from June 13, 2025, to July 31, 2025. The notice also not

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Estrella Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-072746

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.